Document is current

Article History

Received: 21 February 2026

Accepted: 1 June 2026

First Online: 6 June 2026

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee Bern, Switzerland (ID 2023 − 00112).

: General consent to re-use already acquired imaging for scientific purpose was obtained from all individual participants included in the study. No biologic material was used in the present study.

: LS, RF, SB, FL, PS and MG have nothing to disclose. Unrelated to this specific study, BM declares research grants from AbbVie, Protagen, and Novartis Biomedical Research; declares an mir-29 patent for the treatment of systemic sclerosis (US8247389, EP2331143); declares lecturing fees from Boehringer Ingelheim, GaxoSmithKline, Novartis, Otsuka, and Merck Sharpe & Dohme, Lilly; declares consulting fees from Novartis, Boehringer Ingelheim, Janssen-Cilag, and GaxoSmithKline; declares financial support for congresses (i.e., for registration fees and travel) from Medtalk, Pfizer, Roche, Actelion, Mepha, Boehringer Ingelheim, and Merck Sharpe & Dohme; and has been on an advisory board for Janssen and Boehringer. Axel Rominger and Federico Caobelli are Editors of this Journal. Federico Caobelli receives research grants from the Swiss National Science Foundation and Innosuisse and speaker Honoraria from Bracco AG, Blue Earth Diagnostics, Siemens and Pfizer for matters not related to the present work. No other potential conflicts of interest exist.